PCIA
ARKG icon

Prime Capital Investment Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Prime Capital Investment Advisors’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,566
Closed -$240K – 972
2025
Q1 		$240K Buy
+11,566
New +$291K ﹤0.01% 913
2021
Q2 		– Sell
-94
Closed -$8K – 389
2021
Q1 		$8K Buy
+94
New +$9.32K ﹤0.01% 424

Other funds holding ARKG

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Prime Capital Investment Advisors's ARKG Position: Q2 2025 in Review

Prime Capital Investment Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2025, closing a stake of 11,566 shares — an estimated $240K sold.

Prime Capital Investment Advisors first reported a position in ARKG in Q1 2021 and held it in 2 quarters. The position peaked at $240K in Q1 2025. 214 funds tracked by Wall St. Rank hold ARKG as of Q2 2025.

  • Prime Capital Investment Advisors reported no remaining ARK Genomic Revolution ETF position as of Q2 2025 after selling out during the quarter.
  • Prime Capital Investment Advisors sold 11,566 ARK Genomic Revolution ETF shares in Q2 2025, an estimated $240K.
  • Prime Capital Investment Advisors first reported a position in ARK Genomic Revolution ETF in Q1 2021 and held it in 2 quarters.
  • Prime Capital Investment Advisors's ARK Genomic Revolution ETF position peaked at $240K in Q1 2025.
  • 214 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2025.

Based on Prime Capital Investment Advisors's 13F filing for Q2 2025, filed 23 Jul 2025.